EGFR and non-small cell lung carcinoma: Multiple randomized phase III studies found both first- and second-generation EGFR-TKIs, gefitinib, erlotinib, and afatinib to significantly improve overall survival in advanced EGFR-mutated NSCLC as compared to standard, platinum-based combination chemotherapy [15,16].